You are herePharma News
A new protein is being identified by researchers which regulates the severity of tissue damage caused by rheumatoid arthritis (RA), an autoimmune disease that causes inflammation, pain, stiffness and damage to the joints of the feet, hips, knees, and hands. The findings were detailed in the scientific journal PNAS.
A magnetic stimulation therapy for five sessions a week can help people afflicted with Parkinson's disease (PD) walk, new research has found. The study was published in the journal Restorative Neurology and Neuroscience.
BPL Medical Technologies Private Ltd announced the acquisition of Penlon Ltd, a UK-based leading global manufacturer of anaesthesia systems and vaporisers with worldwide distribution networks.
Young adults who spend more time watching television each day are more likely to obese, says a new research. The research is published online in the journal SAGE Open. The study is a 15-year analysis by the University Of Pittsburgh Graduate School Of Public Health.
A survey has found that over 11 per cent people in Delhi are suffering from Asthma and Rhinits, the government today said while acknowledging that air pollution is an "aggravating" factor for respiratory and cardiovascular diseases. "As per a survey conducted by Vallabbhai Patel Chest Institute Delhi in 2006, which covered 5,900 adults belonging to urban, rural and slum population in Delhi, 11.69 per cent were found to be suffering from Rhinits and 11.03 per cent from Asthma," Health Minister J P Nadda informed the Lok °Sabha.
(NewsVoir); The Herbalife Family Foundation (HFF), a non-profit organization dedicated to improving the lives of children by helping charitable organizations provide healthy nutrition to children in need, today announced the launch of the third phase of Casa Herbalife program with Smile Foundation, a national development organization that works for underprivileged children and youth in education, healthcare, livelihoods and women’s empowerment. During the third phase unveiled today in Bangalore, the HFF will extend grants to provide nutritional support to 1,000 children across India, through Smile Foundation’s ‘Mission Education’ program.
Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, is announced the appointment of Umang Vohra as Global Chief Financial and Strategy Officer and Prabir Jha as Global Chief People Officer effective 1st October 2015.
~ Creates a leading Global Established Pharmaceutical (GEP) Business
~ Expected to be immediately accretive to adjusted diluted EPS upon closing; $0.10-$0.12 accretion to adjusted diluted EPS expected in first full year after close with additional accretion anticipated thereafter.
Pfizer Inc. announced that it has completed its acquisition of Hospira, Inc.
“We are pleased that Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, is now part of Pfizer. We want to welcome our new Hospira colleagues to Pfizer. We are excited to add their talents and proud of the shared commitment of all Pfizer colleagues to serving patients worldwide,” said Ian Read, chairman and chief executive officer, Pfizer. “We believe that through this transaction, we’ve created value for our shareholders by delivering incremental revenue and expected EPS growth in the near-term by strengthening our GEP business and positioning it for future growth.”
Drugs Technical Advisory Board (DTAB) recommended that only Registered Pharmacist may eligible for getting approval of wholesale license of medicines in 70th meeting of DTAB held on 18th August, 2015 at central drugs standard control organization (CDSCO).
~ Through the acquisition of InvaGen, Cipla gains scale in the US generics market with a strong manufacturing and R&D base, access to broad product portfolio and a strong customer base consisting of top wholesalers/retailers
~ Through the acquisition of Exelan, Cipla gains access to the government and institutional market in the US
Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain closing conditions, is valued at $550 million and will be an all cash transaction. The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.